Pura Vida Investments LLC Acquires 3,669 Shares of Zogenix, Inc. (ZGNX)

Pura Vida Investments LLC increased its position in shares of Zogenix, Inc. (NASDAQ:ZGNX) by 8.1% during the 4th quarter, HoldingsChannel reports. The fund owned 48,887 shares of the company’s stock after purchasing an additional 3,669 shares during the period. Zogenix makes up about 1.1% of Pura Vida Investments LLC’s portfolio, making the stock its 25th biggest holding. Pura Vida Investments LLC’s holdings in Zogenix were worth $1,782,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Wells Fargo & Company MN lifted its position in Zogenix by 4.0% during the third quarter. Wells Fargo & Company MN now owns 35,403 shares of the company’s stock worth $1,755,000 after buying an additional 1,355 shares during the period. SG Americas Securities LLC acquired a new stake in Zogenix during the third quarter worth about $109,000. JPMorgan Chase & Co. increased its stake in Zogenix by 53.7% during the third quarter. JPMorgan Chase & Co. now owns 75,721 shares of the company’s stock worth $3,756,000 after acquiring an additional 26,445 shares during the last quarter. Candriam Luxembourg S.C.A. increased its stake in Zogenix by 35.9% during the third quarter. Candriam Luxembourg S.C.A. now owns 108,700 shares of the company’s stock worth $5,392,000 after acquiring an additional 28,700 shares during the last quarter. Finally, Prudential Financial Inc. acquired a new stake in Zogenix during the third quarter worth about $219,000.

ZGNX stock opened at $51.88 on Friday. Zogenix, Inc. has a 1 year low of $33.43 and a 1 year high of $62.75. The stock has a market capitalization of $2.19 billion, a PE ratio of -16.06 and a beta of 2.18.

In other news, CEO Stephen J. Farr sold 90,313 shares of the stock in a transaction dated Thursday, January 10th. The stock was sold at an average price of $45.00, for a total value of $4,064,085.00. Following the completion of the sale, the chief executive officer now owns 52,259 shares in the company, valued at $2,351,655. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Roger Hawley sold 60,000 shares of the stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $52.99, for a total value of $3,179,400.00. Following the completion of the sale, the director now owns 49,364 shares of the company’s stock, valued at approximately $2,615,798.36. The disclosure for this sale can be found here. In the last quarter, insiders sold 201,096 shares of company stock valued at $9,754,936. Insiders own 4.60% of the company’s stock.

ZGNX has been the subject of several research analyst reports. BidaskClub upgraded Zogenix from a “hold” rating to a “buy” rating in a research note on Wednesday, January 9th. Zacks Investment Research upgraded Zogenix from a “sell” rating to a “hold” rating in a research note on Saturday, February 2nd. Finally, Mizuho restated a “buy” rating and set a $69.00 price target on shares of Zogenix in a research note on Wednesday, February 6th. One investment analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Zogenix currently has a consensus rating of “Buy” and an average target price of $70.00.

ILLEGAL ACTIVITY WARNING: This news story was originally published by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The correct version of this news story can be viewed at https://sportsperspectives.com/2019/03/17/pura-vida-investments-llc-acquires-3669-shares-of-zogenix-inc-zgnx.html.

Zogenix Company Profile

Zogenix, Inc, a pharmaceutical company, develops and commercializes therapies for the treatment of transformative central nervous system disorders in the United States. Its lead product candidate is the Fintepla/ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome.

Further Reading: Return On Assets

Want to see what other hedge funds are holding ZGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zogenix, Inc. (NASDAQ:ZGNX).

Institutional Ownership by Quarter for Zogenix (NASDAQ:ZGNX)

Receive News & Ratings for Zogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix and related companies with MarketBeat.com's FREE daily email newsletter.